LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

LLY

988.07

+2.29%↑

JNJ

193.84

+3.17%↑

UNH

327.41

+1.82%↑

NVS

130.21

+2.49%↑

ABT

126.93

+0.93%↑

Kodu・Aktsiate loetelu・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Suletud

SektorTervishoid

10.34 2.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

9.99

Max

10.87

Põhinäitajad
By Trading Economics
Sissetulek	11M -20M
Müük	5.9M 40M
Aktsiakasum	-0.19
Kasumimarginaal	-49.569
Töötajad	184
EBITDA	16M -19M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+152.66% upside

Turustatistika
By TradingEconomics
Turukapital	294M 1B
Eelmine avamishind	8.27
Eelmine sulgemishind	10.34

Uudiste sentiment

By Acuity

50%

180 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

6.26 / 7.47 Toetus ja vastupanu

Day One Biopharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. nov 2025, 23:59 UTC

Tulu

Singtel's 1st Half Net Profit Surges

11. nov 2025, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11. nov 2025, 22:21 UTC

Tulu

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11. nov 2025, 23:52 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11. nov 2025, 23:44 UTC

Tulu

Singtel's 1H Net Profit Surges

11. nov 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11. nov 2025, 23:18 UTC

Tulu

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11. nov 2025, 23:15 UTC

Tulu

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11. nov 2025, 23:14 UTC

Tulu

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11. nov 2025, 23:12 UTC

Tulu

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11. nov 2025, 23:11 UTC

Tulu

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11. nov 2025, 23:10 UTC

Tulu

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11. nov 2025, 23:04 UTC

Market Talk

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11. nov 2025, 21:50 UTC

Market Talk

Tulu

Health Care Roundup: Market Talk

11. nov 2025, 21:46 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11. nov 2025, 21:41 UTC

Tulu

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11. nov 2025, 21:40 UTC

Tulu

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11. nov 2025, 21:39 UTC

Tulu

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11. nov 2025, 21:38 UTC

Tulu

Aristocrat: Final Dividend 49 Australian Cents/Share

11. nov 2025, 21:37 UTC

Tulu

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11. nov 2025, 21:36 UTC

Tulu

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11. nov 2025, 21:35 UTC

Tulu

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Adj EPS 79c >ALC

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q Rev $2.61B >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11. nov 2025, 21:35 UTC

Tulu

Alcon 3Q EPS 48c >ALC.EB

Võrdlus sarnastega

Hinnamuutus

Day One Biopharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

152.66% tõus

12 kuu keskmine prognoos

Keskmine 25.67 USD 152.66%

Kõrge 34 USD

Madal 16 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Day One Biopharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Day One Biopharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

6.26 / 7.47Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

180 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.